Bulls On Fire

Novelix Pharmaceuticals financial performance Q3 FY26

Novelix Pharmaceuticals Limited

Written by,

Surjeet Dudani

Feb 13, 2026

Novelix Pharmaceuticals Limited the stock—picked at ₹27.94 in BullsonFire’s “Zero to Hero”—is now trading around ₹63.

Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) has announced its unaudited financial results for the quarter ended 31 December 2025, showing a substantial improvement in operational scale and profitability. Listed on BSE Limited (Scrip Code: 536565), the company operates in Pharmaceutical Research & Analysis and Manufacturing & Trading of Active Pharmaceutical Ingredients (APIs).

The Q3 FY26 results were approved by the Board on 12 February 2026 and reviewed by the statutory auditors, CVS Balachandra Rao & Co., under Regulation 33 of SEBI (LODR) Regulations. The quarter also reflects the impact of a recent preferential allotment that strengthened the company’s capital base.

Q3 FY26 Financial Highlights

For the quarter ended 31 December 2025:

Income from Operations: ₹4,840.25 lakh
Total Income: ₹4,840.27 lakh
Profit Before Tax: ₹128.31 lakh
Net Profit: ₹100.44 lakh
EPS (Basic): ₹0.58

Revenue expansion was primarily driven by higher trading volumes in pharmaceutical activities. While purchase costs remain high, absolute profit improved considerably compared to previous periods.

YoY and QoQ Financial Comparison

Year-on-Year (Q3 FY26 vs Q3 FY25)

Metric	Q3 FY26	Q3 FY25	YoY Change
Revenue	₹4,840.25 L	₹529.98 L	+813%
PBT	₹128.31 L	₹12.80 L	+902%
Net Profit	₹100.44 L	₹14.79 L	+579%
EPS	₹0.58	₹0.15	+287%

The strong YoY rise reflects business restructuring and scale-up compared to the low base of the previous year.

Quarter-on-Quarter (Q3 FY26 vs Q2 FY26)

Metric	Q3 FY26	Q2 FY26	QoQ Change
Revenue	₹4,840.25 L	₹3,635.89 L	+33%
PBT	₹128.31 L	₹71.89 L	+78%
Net Profit	₹100.44 L	₹53.31 L	+88%
EPS	₹0.58	₹0.37	+57%

Sequential growth indicates continued operational momentum during FY26.

Images from Screener.in

Nine-Month FY26 Performance

For the nine months ended 31 December 2025:

Total Income: ₹10,714.52 lakh
Net Profit: ₹164.46 lakh

In the corresponding nine-month period of FY25, the company had reported a net loss of ₹7.65 lakh. This marks a transition from loss to profitability during FY26.

Balance Sheet & Cash Flow

As of September 2025:

Total Assets: ₹71.80 crore
Borrowings: Nil

The company remains debt-free. However, other liabilities increased due to working capital expansion.

Operating cash flow for FY25 was negative, reflecting higher working capital deployment during business scaling. Financing inflows from capital raising supported liquidity.

Shareholding & Capital Update

Promoter holding declined from 66.92% (June 2023) to 50.79% (January 2026) following a preferential issue.

During February 2026, the company allotted 23,20,000 equity shares at ₹60 per share, raising ₹13.92 crore from 36 investors. Paid-up capital increased from ₹17.61 crore to ₹19.93 crore.

Peer Snapshot

Within the Healthcare Research and Analytics space, companies such as:

Syngene International
Indegene Limited
Vimta Labs Limited

operate at significantly larger scale. Novelix Pharmaceuticals Limited, with a market capitalization near ₹101 crore, remains a micro-cap participant and is still in early-stage scaling compared to established peers.

Conclusion

Novelix Pharmaceuticals Limited’s Q3 FY26 results show sharp revenue and profit expansion both year-on-year and sequentially. The combination of operational restructuring and capital infusion has materially increased business scale within a short time.

Margins are still moderate and working capital efficiency needs further improvement, but FY26 so far indicates a meaningful shift in revenue trajectory. Sustaining this scale and improving return ratios will be important in the coming quarters, as consistency will decide how stable this growth actually is.

PDF DOWNLOADABLE VERSION AVAILABLE Download

Disclaimer:- The content available on Bulls On Fire is intended strictly for general informational and educational purpose only. We want to clearly mention that we are not SEBI-registered Research Analysts, and therefore any article, research note, market commentary or insight published here should not be considered as investment advice, stock recommendation, or any kind of financial guidance. Although we try to ensure the information is reasonably accurate and updated, there can be mistakes, delays or unintentional oversights in the material.

Readers and visitors are strongly advised to conduct their own independent research and, whenever needed, seek proper advice from a qualified and SEBI-registered financial professional before making any investment or trading decision. Bulls On Fire and its authors shall not be held responsible or liable, in any manner whatsoever, for any loss, damage or consequences arising from the usage or reliance of the information presented on this website.

Investors: Knowing What Not to Do

Matters More Than Knowing What to Do

In investing, returns often improve naturally when common mistakes are avoided. Over time, by observing and interacting with many investors, certain behavioral patterns clearly stand out. These traits usually indicate investors who struggle to succeed in the stock market.

Investors who panic easily and sell as soon as markets fall slightly.
Those who lack patience and expect fast results.
People who treat the stock market like a gambling platform instead of investing in real businesses.
Investors who borrow money to invest, especially during bull markets.
Individuals who book profits too early without letting investments grow.
Overactive traders who frequently buy and sell but believe they are long-term investors.
Emotional investors whose decisions are driven by market noise or personal life situations.
People who focus more on lifestyle display and status rather than disciplined wealth building.
Investors with irregular income who fail to invest consistently, limiting the power of compounding over time.
Those who stop learning after making some money and lose the drive to grow further.
Investors who blindly follow tips from social media, influencers, or news without doing their own research.
People who don’t review their mistakes and keep repeating the same errors.
Those who ignore risk management and invest without understanding downside possibilities.
Investors who constantly compare their returns with others and make impulsive changes.
People who have no long-term plan and keep changing strategies every few months.

Often, it’s the blind spots we are unaware of that lead to disappointing outcomes. If you recognize any of these traits in yourself, working on them can make a big difference. Stock market investing is a journey of learning first and earning later. Unfortunately, many investors try to earn first and learn later.